{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:16:51Z","timestamp":1791515811119,"version":"4.3.4"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-11127-5","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:10:34Z","timestamp":1760695834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects"],"prefix":"10.1007","volume":"52","author":[{"given":"Namy","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Al Sabahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Jawaid","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Alam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"11127_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155379","volume":"128","author":"CD Mohan","year":"2024","unstructured":"Mohan CD, Shanmugam MK, Gowda SG, Chinnathambi A, Rangappa KS, Sethi G (2024) C-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy. Phytomedicine 128:155379","journal-title":"Phytomedicine"},{"issue":"1","key":"11127_CR2","first-page":"5179182","volume":"2022","author":"A Faiella","year":"2022","unstructured":"Faiella A, Riccardi F, Carten\u00ec G, Chiurazzi M, Onofrio L (2022) The emerging role of c-met in carcinogenesis and clinical implications as a possible therapeutic target. J Oncol 2022(1):5179182","journal-title":"J Oncol"},{"key":"11127_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, Zeng Z (2018) Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 17:1\u20134","journal-title":"Mol Cancer"},{"issue":"2","key":"11127_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12(2):89\u2013103. https:\/\/doi.org\/10.1038\/nrc3205","journal-title":"Nat Rev Cancer"},{"key":"11127_CR5","unstructured":"European Bioinformatics Institute ChEMBL database [Internet]. Hinxton (UK): EMBL-EBI; [cited 2025 Mar 31]. Available from: https:\/\/www.ebi.ac.uk\/chembl\/"},{"key":"11127_CR6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","volume":"7","author":"PM Comoglio","year":"2008","unstructured":"Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504\u2013516","journal-title":"Nat Rev Drug Discov"},{"issue":"1suppl","key":"11127_CR7","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","volume":"3","author":"SL Organ","year":"2011","unstructured":"Organ SL, Tsao MS (2011) An overview of the c-MET signaling pathway. Ther Adv Med Oncol 3(1suppl):S7-19","journal-title":"Ther Adv Med Oncol"},{"key":"11127_CR8","doi-asserted-by":"crossref","unstructured":"Ariyawutyakorn W, Saichaemchan S, Garcia MV, Understanding and targeting MET signaling in solid tumors - are we there yet? J. Cancer. 7 633\u2013649. doi:, Petrini ANDI (2016) Biology of MET: a double life between normal tissue repair and tumor progression, Ann. Transl. Med. 3 (2015) 82. doi: 10.3978\/j.issn.2305-5839.2015.03.58","DOI":"10.7150\/jca.12663"},{"key":"11127_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.biocel.2014.01.009","volume":"49","author":"R Barrow-Mcgee","year":"2014","unstructured":"Barrow-Mcgee R, Kermorgant S (2014) Met endosomal signalling: in the right place, at the right time. Int J Biochem Cell Biol 49:69\u201374. https:\/\/doi.org\/10.1016\/j.biocel.2014.01.009","journal-title":"Int J Biochem Cell Biol"},{"key":"11127_CR10","first-page":"969","volume":"4","author":"RA Parikh","year":"2014","unstructured":"Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ (2014) The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther 4:969\u2013983","journal-title":"Onco Targets Ther"},{"issue":"4","key":"11127_CR11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/13543784.2018.1462336","volume":"27","author":"G Pasquini","year":"2018","unstructured":"Pasquini G, Giaccone G (2018) C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs 27(4):363\u2013375","journal-title":"Expert Opin Investig Drugs"},{"key":"11127_CR12","unstructured":"NCBI MET proto-oncogene, receptor tyrosine kinase [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; updated 6 Jul 2025 [cited 2025 Jul 13]. Gene ID: 4233. Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/4233"},{"key":"11127_CR13","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM et al (2015) Tissue-based map of the human proteome. Science. ;347(6220):1260419. 10.1126\/science.1260419.The Human Protein Atlas. RNA expression data in human tissues (version 24.0). Available from https:\/\/www.proteinatlas.org\/humanproteome\/tissue\/data (accessed July 2025)"},{"issue":"10","key":"11127_CR14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","volume":"25","author":"J Wolf","year":"2024","unstructured":"Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, Orlov SV, Vansteenkiste J, Nishio M, de Jonge M, Akerley W (2024) Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol 25(10):1357\u20131370","journal-title":"Lancet Oncol"},{"issue":"10","key":"11127_CR15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J (2020) Tepotinib in non\u2013small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383(10):931\u2013943","journal-title":"N Engl J Med"},{"issue":"1","key":"11127_CR16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40360-025-00859-6","volume":"26","author":"H Zhang","year":"2025","unstructured":"Zhang H, Song Y, Xia F, Liu Y, Zhang L, Yang J, Tu H, Long B, Sui J, Wang Y (2025) Adverse event profile of Crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study. BMC Pharmacol Toxicol 26(1):61","journal-title":"BMC Pharmacol Toxicol"},{"issue":"8","key":"11127_CR17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","volume":"6","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Heng DY, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, Ottesen LH, Frigault MM, L\u2019Hernault A, Szijgyarto Z, Signoretti S (2020) Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol 6(8):1247\u20131255","journal-title":"JAMA Oncol"},{"issue":"2","key":"11127_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","volume":"31","author":"TK Choueiri","year":"2013","unstructured":"Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH (2013) Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 31(2):181\u2013186","journal-title":"J Clin Oncol"},{"key":"11127_CR19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102333","volume":"103","author":"B McGregor","year":"2022","unstructured":"McGregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB (2022) Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review. Cancer Treat Rev 103:102333","journal-title":"Cancer Treat Rev"},{"key":"11127_CR20","doi-asserted-by":"crossref","unstructured":"Dong Y, Xu J, Sun B, Wang J, Wang Z. (2022). MET-targeted therapies and clinical outcomes: A systematic literature review. Molecular Diagnosis & Therapy 26:203\u2013227.","DOI":"10.1007\/s40291-021-00568-w"},{"key":"11127_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13000-015-0362-5","volume":"10","author":"I Watermann","year":"2015","unstructured":"Watermann I, Schmitt B, Stellmacher F et al (2015) Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol 10:130","journal-title":"Diagn Pathol"},{"issue":"7","key":"11127_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","volume":"10","author":"G Recondo","year":"2020","unstructured":"Recondo G, Che J, J\u00e4nne PA, Awad MM (2020) Targeting MET dysregulation in cancer. Cancer Discov 10(7):922\u2013934. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1446","journal-title":"Cancer Discov"},{"key":"11127_CR23","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","volume":"14","author":"R Guo","year":"2019","unstructured":"Guo R, Berry LD, Aisner DL et al (2019) MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the lung cancer mutation consortium. J Thorac Oncol 14:1666\u20131671","journal-title":"J Thorac Oncol"},{"key":"11127_CR24","volume":"8","author":"J Zhou","year":"2023","unstructured":"Zhou J, Zhang XC, Xue S (2023) SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer. Signal Transduct Target Ther 8:185","journal-title":"Signal Transduct Target Ther"},{"key":"11127_CR25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","volume":"111","author":"L Bubendorf","year":"2017","unstructured":"Bubendorf L, Dafni U, Schobel M et al (2017) Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European thoracic oncology platform (ETOP) lungscape project. Lung Cancer 111:143\u2013149","journal-title":"Lung Cancer"},{"issue":"1","key":"11127_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03999-7","volume":"21","author":"D Sun","year":"2023","unstructured":"Sun D, Wu W, Wang L, Qu J, Han Q, Wang H, Song S, Liu N, Wang Y, Hou H (2023) Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer. J Transl Med 21(1):150. https:\/\/doi.org\/10.1186\/s12967-023-03999-7","journal-title":"J Transl Med"},{"key":"11127_CR27","doi-asserted-by":"crossref","first-page":"e441e463","DOI":"10.1016\/j.cllc.2018.03.010","volume":"19","author":"H Reis","year":"2018","unstructured":"Reis H, Metzenmacher M, Goetz M et al (2018) MET expression in advanced non-small-cell lung cancer: effect on 10 Han et al JTO clinical and research reports 5 No. clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. Clin Lung Cancer 19:e441e463","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"11127_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1055-9965.EPI-10-1080","volume":"20","author":"YY Janjigian","year":"2011","unstructured":"Janjigian YY, Tang LH, Coit DG et al (2011) MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20(5):1021\u20131027. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-1080","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"11127_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/bjc.2012.237","volume":"107","author":"HE Lee","year":"2012","unstructured":"Lee HE, Kim MA, Lee HS et al (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107(2):325\u2013333. https:\/\/doi.org\/10.1038\/bjc.2012.237","journal-title":"Br J Cancer"},{"issue":"1","key":"11127_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11670-012-0018-x","volume":"24","author":"Y Sun","year":"2012","unstructured":"Sun Y, Tian -M-M, Zhou L-X, You W-C, Li J-Y (2012) Value of c-Met for predicting progression of precancerous gastric lesions in rural Chinese population. Chin J Cancer Res 24(1):18\u201322. https:\/\/doi.org\/10.1007\/s11670-012-0018-x","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"11127_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/1535-7163.MCT-11-0754","volume":"11","author":"C Chen","year":"2012","unstructured":"Chen C, Kim H, Liska D et al (2012) MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 11(3):660\u2013669. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0754","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"11127_CR32","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1172\/JCI75200","volume":"124","author":"J Kim","year":"2014","unstructured":"Kim J, Fox C, Peng S (2014) Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest 124(12):5145\u20135158. https:\/\/doi.org\/10.1172\/JCI75200","journal-title":"J Clin Invest"},{"key":"11127_CR33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ejmech.2015.12.016","volume":"108","author":"J Zhang","year":"2016","unstructured":"Zhang J, Jiang X, Jiang Y et al (2016) Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Eur J Med Chem 108:495\u2013504","journal-title":"Eur J Med Chem"},{"key":"11127_CR34","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1074\/jbc.275.12.8806","volume":"275","author":"M Jo","year":"2000","unstructured":"Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC (2000) Crosstalk between epidermal growth factor receptor and cMet signal pathways in transformed cells. J Biol Chem 275:8806\u20138811","journal-title":"J Biol Chem"},{"key":"11127_CR35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K et al (2018) Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 17:45","journal-title":"Mol Cancer"},{"key":"11127_CR36","first-page":"294","volume":"40","author":"K Huang","year":"2018","unstructured":"Huang K, Sung I, Fang W et al (2018) Correlation between HGF\/c-Met and Notch1 signaling pathways in human gastric cancer cells. Oncol Rep 40:294\u2013230","journal-title":"Oncol Rep"},{"key":"11127_CR37","volume":"8","author":"H Wang","year":"2020","unstructured":"Wang H, Rao B, Lou J et al (2020) The function of the HGF\/c-Met axis in hepatocellular carcinoma. Front Cell Dev Biol 8:55","journal-title":"Front Cell Dev Biol"},{"key":"11127_CR38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12957-022-02659-2","volume":"20","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Miao L, Wang S et al (2022) Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis. World J Surg Oncol 20:204. https:\/\/doi.org\/10.1186\/s12957-022-02659-2","journal-title":"World J Surg Oncol"},{"issue":"5","key":"11127_CR39","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.21037\/jgo-21-536","volume":"12","author":"X Lai","year":"2021","unstructured":"Lai X, Dong Q, Xu F, Wu S, Yang D, Liu C, Li Y, Li Z, Ma D (2021) Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer. J Gastrointest Oncol 12(5):2203\u20132210. https:\/\/doi.org\/10.21037\/jgo-21-536","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"11127_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16(1):68\u201373. https:\/\/doi.org\/10.1038\/ng0597-68","journal-title":"Nat Genet"},{"issue":"8","key":"11127_CR41","first-page":"1719","volume":"58","author":"L Schmidt","year":"1998","unstructured":"Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, Zhuang Z, Jeffers M, Vande Woude G, Neumann H, Walther M, Linehan WM, Zbar B (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58(8):1719\u20131722 PMID: 9563489","journal-title":"Cancer Res"},{"issue":"1","key":"11127_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/1727","volume":"20","author":"Z Zhuang","year":"1998","unstructured":"Zhuang Z, Park WS, Pack S, Schmidt L, Vortmeyer AO, Pak E, Pham T, Weil RJ, Candidus S, Lubensky IA, Linehan WM, Zbar B, Weirich G (1998) Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20(1):66\u20139. https:\/\/doi.org\/10.1038\/1727","journal-title":"Nat Genet"},{"issue":"3","key":"11127_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/humu.24313","volume":"43","author":"M Sebai","year":"2022","unstructured":"Sebai M, Tulasne D, Caputo SM, Verkarre V, Fernandes M, Gu\u00e9rin C, Reinhart F, Adams S, Maugard C, Caron O, Guillaud-Bataille M, Berthet P, Bignon YJ, Bressac-de Paillerets B, Burnichon N, Chiesa J, Giraud S, Lejeune S, Limacher JM, de Pauw A, Stoppa-Lyonnet D, Zattara-Cannoni H, Deveaux S, Lidereau R, Richard S, Rouleau E (2022) Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. Hum Mutat 43(3):316\u2013327. https:\/\/doi.org\/10.1002\/humu.24313Epub 2022 Jan 19. PMID: 34882875","journal-title":"Hum Mutat"},{"issue":"21","key":"11127_CR44","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1073\/pnas.94.21.11445","volume":"94","author":"M Jeffers","year":"1997","unstructured":"Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF (1997) Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 94(21):11445\u201311450. https:\/\/doi.org\/10.1073\/pnas.94.21.11445","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"11127_CR45","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1073\/pnas.95.24.14379","volume":"95","author":"A Bardelli","year":"1998","unstructured":"Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P, Comoglio PM (1998) Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci U S A 95(24):14379\u201314383. https:\/\/doi.org\/10.1073\/pnas.95.24.14379","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"11127_CR46","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1038\/sj.onc.1202899","volume":"18","author":"P Michieli","year":"1999","unstructured":"Michieli P, Basilico C, Pennacchietti S, Maff\u00e8 A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM (1999) Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18(37):5221\u201331. https:\/\/doi.org\/10.1038\/sj.onc.1202899","journal-title":"Oncogene"},{"issue":"2","key":"11127_CR47","first-page":"307","volume":"59","author":"WS Park","year":"1999","unstructured":"Park WS et al (1999) Somatic mutations in the kinase domain of the Met\/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59(2):307\u2013310","journal-title":"Cancer Res"},{"issue":"6","key":"11127_CR48","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.oraloncology.2005.10.016","volume":"42","author":"S Hara","year":"2006","unstructured":"Hara S et al (2006) Hypoxia enhances c-Met\/HGF receptor expression and signaling by activating HIF-1\u03b1 in human salivary gland cancer cells. Oral Oncol 42(6):593\u2013598. https:\/\/doi.org\/10.1016\/j.oraloncology.2005.10.016","journal-title":"Oral Oncol"},{"key":"11127_CR49","doi-asserted-by":"publisher","unstructured":"Klosek SK et al (2005) CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochemical and biophysical research communications vol. 336,2 : 408\u2009\u2013\u200916. https:\/\/doi.org\/10.1016\/j.bbrc.2005.08.106","DOI":"10.1016\/j.bbrc.2005.08.106"},{"issue":"1","key":"11127_CR50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbrc.2008.03.042","volume":"370","author":"S Hara","year":"2008","unstructured":"Hara S, Nakashiro KI, Goda H, Hamakawa H (2008) Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun 370(1):123\u2013128","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"11127_CR51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/00016480510037014","volume":"126","author":"CH Kim","year":"2006","unstructured":"Kim CH, Moon SK, Bae JH, Ho Lee J, Ho Han J, Kim K, Chang Choi E (2006) Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 126(1):88\u201394","journal-title":"Acta Otolaryngol"},{"issue":"Suppl 4","key":"11127_CR52","volume":"30","author":"R Segovia","year":"2019","unstructured":"Segovia R, Arroyo G, Ituarte C, Inklemona C, Rojo S, Salvatierra A, Berlinghieri G, Saucedo S, Monteros Alvi M, Lamas R (2019) Over-expression of c-MET in biliary tract cancer: prevalence and clinical-molecular correlation (ILOGI). Ann Oncol 30(Suppl 4):iv72 Abstract P-263","journal-title":"Ann Oncol"},{"issue":"6","key":"11127_CR53","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ajhg.2015.11.001","volume":"97","author":"MJ Gray","year":"2015","unstructured":"Gray MJ et al (2015) Mutations preventing regulated exon skipping in MET cause osteofibrous dysplasia. Am J Hum Genet 97(6):837\u2013847. https:\/\/doi.org\/10.1016\/j.ajhg.2015.11.001","journal-title":"Am J Hum Genet"},{"key":"11127_CR54","first-page":"6272","volume":"63","author":"PC Ma","year":"2003","unstructured":"Ma PC, Kijima T, Maulik G et al (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272\u20136281","journal-title":"Cancer Res"},{"issue":"5","key":"11127_CR55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/138161213804547196","volume":"19","author":"J Voortman","year":"2013","unstructured":"Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G (2013) Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des 19(5):833\u2013840","journal-title":"Curr Pharm Des"},{"key":"11127_CR56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2018.06.001","volume":"122","author":"Y Li","year":"2018","unstructured":"Li Y, Gao L, Ma D, Qiu T, Li W, Li W, Guo L, Xing P, Liu B, Deng L, Fu J (2018) Identification of MET exon14 skipping by targeted DNA-and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. Lung Cancer 122:113\u2013119","journal-title":"Lung Cancer"},{"issue":"4","key":"11127_CR57","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","volume":"14","author":"KD Davies","year":"2019","unstructured":"Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, Camidge DR, Aisner DL (2019) DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. J Thorac Oncol 14(4):737\u2013741","journal-title":"J Thorac Oncol"},{"key":"11127_CR58","doi-asserted-by":"crossref","unstructured":"Jurkiewicz, M., Saqi, A., Mansukhani, M. M., et al. (2020). Efficacy of DNA versus RNA NGS-based Methods in MET Exon 14 skipping mutation detection. Journal of Clinical Oncology 38(15_suppl):9036\u20139036.","DOI":"10.1200\/JCO.2020.38.15_suppl.9036"},{"issue":"3","key":"11127_CR59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00418-008-0479-7","volume":"130","author":"SM Farragher","year":"2008","unstructured":"Farragher SM, Tanney A, Kennedy RD, Paul Harkin D (2008) RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 130(3):435\u2013445","journal-title":"Histochem Cell Biol"},{"issue":"11","key":"11127_CR60","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036798","volume":"9","author":"WR McCombie","year":"2019","unstructured":"McCombie WR, McPherson JD, Mardis ER (2019) Next-generation sequencing technologies. Cold Spring Harb Perspect Med 9(11):a036798","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"11127_CR61","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jtho.2017.07.026","volume":"12","author":"B Poirot","year":"2017","unstructured":"Poirot B, Doucet L, Benhenda S, Champ J, Meignin V, Lehmann-Che J (2017) MET exon 14 alterations and new resistance mutations to tyrosine kinase inhibitors: risk of inadequate detection with current amplicon-based NGS panels. J Thorac Oncol 12(10):1582\u20131587","journal-title":"J Thorac Oncol"},{"issue":"9","key":"11127_CR62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumors\u2014molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17(9):569\u2013587","journal-title":"Nat Rev Clin Oncol"},{"key":"11127_CR63","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-14-2683","volume":"21","author":"A Drilon","year":"2015","unstructured":"Drilon A, Wang L, Arcila ME (2015) Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 21:3631\u20133639","journal-title":"Clin Cancer Res"},{"issue":"3","key":"11127_CR64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0022-2836(75)90213-2","volume":"94","author":"F Sanger","year":"1975","unstructured":"Sanger F, Coulson AR (1975) A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 94(3):441\u2013448","journal-title":"J Mol Biol"},{"issue":"12","key":"11127_CR65","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","volume":"74","author":"F Sanger","year":"1977","unstructured":"Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74(12):5463\u20137","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"11127_CR66","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.3390\/cancers14194814","volume":"14","author":"R Das","year":"2022","unstructured":"Das R, Jakubowski MA, Spildener J, Cheng YW (2022) Identification of novel MET exon 14 skipping variants in non-small cell lung cancer patients: a prototype workflow involving in silico prediction and RT-PCR. Cancers 14(19):4814. https:\/\/doi.org\/10.3390\/cancers14194814","journal-title":"Cancers"},{"issue":"14","key":"11127_CR67","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1242\/jcs.00633","volume":"116","author":"JM Levsky","year":"2003","unstructured":"Levsky JM, Singer RH (2003) Fluorescence in situ hybridization: past, present and future. J Cell Sci 116(14):2833\u20132838","journal-title":"J Cell Sci"},{"key":"11127_CR68","volume":"16","author":"P Yuan","year":"2024","unstructured":"Yuan P, Xue X, Qiu T, Ying J (2024) MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature. Ther Adv Med Oncol 16:17588359231221910","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"11127_CR69","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PG, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY (2019) Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov 9(10):1388\u20131405","journal-title":"Cancer Discov"},{"key":"11127_CR70","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.csbj.2019.09.003","volume":"17","author":"C Heydt","year":"2019","unstructured":"Heydt C, Becher AK, Wagener-Ryczek S (2019) Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors. Comput Struct Biotechnol J 17:1339\u20131347","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"11127_CR71","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00432-022-04048-4","volume":"149","author":"Y Fan","year":"2023","unstructured":"Fan Y, Sun R, Wang Z, Zhang Y, Xiao X, Liu Y, Xin B, Xiong H, Lu D, Ma J (2023) Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer. J Cancer Res Clin Oncol 149(5):1667\u20131677","journal-title":"J Cancer Res Clin Oncol"},{"key":"11127_CR72","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo R, Luo J, Chang J et al (2020) MET-dependent solid tumors - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17:569\u2013587","journal-title":"Nat Rev Clin Oncol"},{"key":"11127_CR73","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","volume":"31","author":"DR Spigel","year":"2013","unstructured":"Spigel DR, Ervin TJ, Ramlau RA et al (2013) Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105\u20134114","journal-title":"J Clin Oncol"},{"key":"11127_CR74","unstructured":"score MS, Post-Calculating CASCO (2015) H-Score. https:\/\/www.ascopost.com\/issues\/april-10-2015\/calculating-h-score\/"},{"issue":"149","key":"11127_CR75","volume":"5","author":"M Seager","year":"2019","unstructured":"Seager M, Aisner DL, Davies KD (2019) Oncogenic gene fusion detection using anchored multiplex polymerase chain reaction followed by next generation sequencing. JoVE (Journal Visualized Experiments) 5(149):e59895","journal-title":"JoVE (Journal Visualized Experiments)"},{"key":"11127_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.06.001","author":"Y Li","year":"2018","unstructured":"Li Y, Gao L, Ma D, Qiu T, Li W, Li W, Guo L, Xing P, Liu B, Deng L, Fu J, Li J, Yu Y, Ying J (2018) Identification of MET exon14 skipping by targeted DNAand RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. Lung Cancer. https:\/\/doi.org\/10.1016\/j.lungcan.2018.06.001","journal-title":"Lung Cancer"},{"issue":"1","key":"11127_CR77","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1373\/clinchem.2019.308833","volume":"66","author":"Z Song","year":"2020","unstructured":"Song Z, Xu C, He Y, Li F, Wang W, Zhu Y, Gao Y, Ji M, Chen M, Lai J, Cheng W (2020) Simultaneous detection of gene fusions and base mutations in cancer tissue biopsies by sequencing dual nucleic acid templates in unified reaction. Clin Chem 66(1):178\u2013187","journal-title":"Clin Chem"},{"issue":"10","key":"11127_CR78","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.3390\/cancers12102843","volume":"12","author":"J Wei","year":"2020","unstructured":"Wei J, Rybczynska AA, Meng P, Terpstra M, Saber A, Sietzema J, Timens W, Schuuring E, Hiltermann TJ, Groen HJ, van der Wekken AJ (2020) An all-in-one transcriptome-based assay to identify therapy-guiding genomic aberrations in nonsmall cell lung cancer patients. Cancers 12(10):2843","journal-title":"Cancers"},{"key":"11127_CR79","first-page":"294","volume":"40","author":"K Huang","year":"2018","unstructured":"Huang K, Sung I, Fang W et al (2018) Correlation between HGF\/c-Met and Notch1 signaling pathways in human gastric cancer cells. Oncol Rep 40:294\u2013302","journal-title":"Oncol Rep"},{"issue":"6","key":"11127_CR80","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3727\/096504014X13946388748956","volume":"21","author":"Y Funakoshi","year":"2013","unstructured":"Funakoshi Y, Mukohara T, Ekyalongo RC, Tomioka H, Kataoka Y, Shimono Y, Chayahara N, Toyoda M, Kiyota N, Fujiwara Y, Minami H (2013) Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells. Oncol Res 21(6):287\u2013293","journal-title":"Oncol Res"},{"key":"11127_CR81","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s10637-013-9959-2","volume":"31","author":"Y Funakoshi","year":"2013","unstructured":"Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H (2013) Excessive MET signaling causes resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Investig New Drugs 31:1158\u20131168","journal-title":"Investig New Drugs"},{"issue":"16","key":"11127_CR82","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1158\/1078-0432.CCR-16-3273","volume":"23","author":"A Li","year":"2017","unstructured":"Li A, Yang JJ, Zhang XC, Zhang Z, Su J, Gou LY, Bai Y, Zhou Q, Yang Z, Han-Zhang H, Zhong WZ (2017) Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non\u2013small cell lung cancer. Clin Cancer Res 23(16):4929\u20134937","journal-title":"Clin Cancer Res"},{"key":"11127_CR83","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H et al (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673\u2013684","journal-title":"Gut"},{"key":"11127_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610697","author":"J Ko","year":"2022","unstructured":"Ko J, Jung J, Kim ST, Hong JY, Park S, Park JO, Park YS, Lim HY, Ahn S, Kim KM, Kang WK (2022) MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer. Pathol Oncol Res. 1610697. https:\/\/doi.org\/10.3389\/pore.2022.1610697","journal-title":"Pathol Oncol Res"},{"key":"11127_CR85","volume":"13","author":"M Yang","year":"2024","unstructured":"Yang M, Mandal E, Liu FX, O\u2019Hara Jr RM, Lesher B, Sanborn RE (2024) Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments. Front Oncol 13:1241402","journal-title":"Front Oncol"},{"issue":"12","key":"11127_CR86","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.humpath.2015.06.025","volume":"46","author":"C Zhu","year":"2015","unstructured":"Zhu C, Xu J, Li M, Zhao G, Cao H (2015) Heterogeneity of c-Met expression in Chinese gastric cancer patients. Hum Pathol 46(12):1901\u20131907","journal-title":"Hum Pathol"},{"issue":"23","key":"11127_CR87","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1158\/1078-0432.CCR-18-0876","volume":"24","author":"M Bahcall","year":"2018","unstructured":"Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC (2018) Amplification of wild-type KRAS imparts resistance to Crizotinib in MET exon 14 mutant non\u2013small cell lung cancer. Clin Cancer Res 24(23):5963\u20135976","journal-title":"Clin Cancer Res"},{"issue":"7","key":"11127_CR88","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.jtho.2019.04.021","volume":"14","author":"W Jin","year":"2019","unstructured":"Jin W, Shan B, Liu H, Zhou S, Li W, Pan J, Lin L, Hu D, Pan Y (2019) Acquired mechanism of Crizotinib resistance in NSCLC with MET exon 14 skipping. J Thorac Oncol 14(7):e137\u2013e139","journal-title":"J Thorac Oncol"},{"issue":"10","key":"11127_CR89","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/2159-8290.CD-12-0237","volume":"2","author":"F Harbinski","year":"2012","unstructured":"Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, Wagner S, Stamm C, Buness A, Chatenay-Rivauday C, Yao Y (2012) Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov 2(10):948\u2013959","journal-title":"Cancer Discov"},{"issue":"7408","key":"11127_CR90","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA (2012) Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500\u2013504","journal-title":"Nature"},{"issue":"7408","key":"11127_CR91","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408):505\u2013509","journal-title":"Nature"},{"issue":"7","key":"11127_CR92","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bbadis.2012.10.013","volume":"1832","author":"T Marsh","year":"2013","unstructured":"Marsh T, Pietras K, McAllister SS (2013) Fibroblasts as architects of cancer pathogenesis. Biochimica et biophysica acta (BBA)-Molecular basis of disease 1832(7):1070\u20131078","journal-title":"Biochimica et biophysica acta (BBA)-Molecular basis of disease"},{"issue":"3","key":"11127_CR93","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.21873\/anticanres.11426","volume":"37","author":"SY Ahn","year":"2017","unstructured":"Ahn SY, Kim J, Kim MA, Choi J, Kim WH (2017) Increased HGF expression induces resistance to c-MET tyrosine kinase inhibitors in gastric cancer. Anticancer Res 37(3):1127\u20131138","journal-title":"Anticancer Res"},{"issue":"36","key":"11127_CR94","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1038\/onc.2016.14","volume":"35","author":"J Cui","year":"2016","unstructured":"Cui J, Xia T, Xie D, Gao Y, Jia Z, Wei D, Wang L, Huang S, Quan M, Xie K (2016) HGF\/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes. Oncogene 35(36):4708\u20134718","journal-title":"Oncogene"},{"issue":"6","key":"11127_CR95","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2018.08.006","volume":"28","author":"M Apicella","year":"2018","unstructured":"Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fern\u00e1ndez-P\u00e9rez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E (2018) Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab 28(6):848\u2013865","journal-title":"Cell Metab"},{"issue":"43","key":"11127_CR96","doi-asserted-by":"crossref","first-page":"27039","DOI":"10.18632\/oncotarget.25472","volume":"9","author":"MS Mekki","year":"2018","unstructured":"Mekki MS, Mougel A, Vinchent A, Paquet C, Copin MC, Leroy C, Kherrouche Z, Bonte JP, Melnyk O, Vicogne J, Tulasne D (2018) Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors. Oncotarget 9(43):27039","journal-title":"Oncotarget"},{"issue":"2","key":"11127_CR97","first-page":"564","volume":"10","author":"X Sun","year":"2020","unstructured":"Sun X, Li CW, Wang WJ, Chen MK, Li H, Lai YJ, Hsu JL, Koller PB, Chan LC, Lee PC, Cheng FJ (2020) Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. Am J Cancer Res 10(2):564","journal-title":"Am J Cancer Res"},{"key":"11127_CR98","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M et al (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21:28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2","journal-title":"Mol Cancer"},{"key":"11127_CR99","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41419-019-1314-x","volume":"10","author":"X Lin","year":"2019","unstructured":"Lin X, Peng Z, Wang X et al (2019) Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. Cell Death Dis 10:139. https:\/\/doi.org\/10.1038\/s41419-019-1314-x","journal-title":"Cell Death Dis"},{"key":"11127_CR100","volume":"33","author":"S Gao","year":"2023","unstructured":"Gao S, Li N, Zhang X, Chen J, Ko BC, Zhao Y (2023) An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to Sorafenib in c-MET\u2009+\u2009hepatocellular carcinoma. Biochem Biophys Rep 33:101412","journal-title":"Biochem Biophys Rep"},{"issue":"6","key":"11127_CR101","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1530\/REP-19-0458","volume":"159","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang H, Zhang Y, Li X, Hu X, Wang X (2020) Decorin promotes apoptosis and autophagy via suppressing c-Met in HTR-8 trophoblasts. Reproduction 159(6):669\u2013677","journal-title":"Reproduction"},{"key":"11127_CR102","doi-asserted-by":"crossref","first-page":"155090","DOI":"10.1016\/j.phymed.2023.155090","volume":"121","author":"R Wang","year":"2023","unstructured":"Wang R, Deng Z, Zhu Z, Wang J, Yang X, Xu M, Wang X, Tang Q, Zhou Q, Wan X, Wu W (2023) Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway. Phytomedicine 121:155090","journal-title":"Phytomedicine"},{"issue":"31","key":"11127_CR103","doi-asserted-by":"crossref","first-page":"51675","DOI":"10.18632\/oncotarget.18386","volume":"8","author":"RD Schroeder","year":"2017","unstructured":"Schroeder RD, Choi W, Hong DS, McConkey DJ (2017) Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. Oncotarget 8(31):51675","journal-title":"Oncotarget"},{"issue":"11","key":"11127_CR104","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/jphp.12140","volume":"65","author":"Y Liu","year":"2013","unstructured":"Liu Y, Liu JH, Chai K, Tashiro SI, Onodera S, Ikejima T (2013) Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. J Pharm Pharmacol 65(11):1622\u20131642","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"11127_CR105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-024-00622-9","volume":"12","author":"P Lyu","year":"2024","unstructured":"Lyu P, Gu X, Wang F, Sun H, Zhou Q, Yang S, Yuan W (2024) Advances in targeting cancer-associated fibroblasts through single-cell spatial transcriptomic sequencing. Biomark Res 12(1):73","journal-title":"Biomark Res"},{"key":"11127_CR106","doi-asserted-by":"crossref","unstructured":"Mahrous M, Jebriel AO, Allehebi A, Shafik A, El Karak F, Venturini F, Alhusaini H, Meergans M, Sendur MA, Ouda M, Al-Nassar M (2023) Consensus recommendations for the Diagnosis, biomarker Testing, and clinical management of advanced or metastatic Non-small cell lung cancer with Mesenchymal-Epithelial transition exon 14 skipping mutations in the middle East, Africa, and Russia. Cureus 15(7):e41992.","DOI":"10.7759\/cureus.41992"},{"key":"11127_CR107","doi-asserted-by":"crossref","first-page":"101063","DOI":"10.1016\/j.neo.2024.101063","volume":"57","author":"MA Simard","year":"2024","unstructured":"Simard MA, Cabrera-Galvez C, Viteri S, Geist F, Reischmann N, Z\u00fchlsdorf M, Karachaliou N (2024) Spatial profiling of METex14-altered NSCLC under Tepotinib treatment: shifting the immunosuppressive landscape. Neoplasia 57:101063","journal-title":"Neoplasia"},{"issue":"1","key":"11127_CR108","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41467-024-55068-2","volume":"16","author":"C Wang","year":"2025","unstructured":"Wang C, Li J, Chen J, Wang Z, Zhu G, Song L, Wu J, Li C, Qiu R, Chen X, Zhang L (2025) Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer. Nat Commun 16(1):1477","journal-title":"Nat Commun"},{"issue":"11","key":"11127_CR109","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.3390\/cancers12113461","volume":"12","author":"VR Silva","year":"2020","unstructured":"Silva VR, Neves SP, Santos LD, Dias RB, Bezerra DP (2020) Challenges and therapeutic opportunities of autophagy in cancer therapy. Cancers 12(11):3461","journal-title":"Cancers"},{"issue":"9","key":"11127_CR110","first-page":"10856","volume":"13","author":"J Wang","year":"2021","unstructured":"Wang J, Wang S, Sun J, Qiu L (2021) Expression of c-MET, EGFR and HER-2 in gastric adenocarcinoma tissue and its relationship with clinicopathological characteristics. Am J Transl Res 13(9):10856","journal-title":"Am J Transl Res"},{"key":"11127_CR111","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s43042-024-00618-y","volume":"25","author":"EM Naguib","year":"2024","unstructured":"Naguib EM, Ismail EF, Badran DI et al (2024) Double trouble: how c-MET and HER2 fuel bladder cancer progression. Egypt J Med Hum Genet 25:147. https:\/\/doi.org\/10.1186\/s43042-024-00618-y","journal-title":"Egypt J Med Hum Genet"},{"issue":"8","key":"11127_CR112","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/JTO.0b013e318257cc89","volume":"7","author":"V Bhardwaj","year":"2012","unstructured":"Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J (2012) C-Met inhibitor MK-8003 radiosensitizes c-Met\u2013expressing non\u2013small-cell lung cancer cells with radiation-induced c-Met\u2013expression. J Thorac Oncol 7(8):1211\u20131217","journal-title":"J Thorac Oncol"},{"issue":"7","key":"11127_CR113","first-page":"3871","volume":"37","author":"T Okuda","year":"2017","unstructured":"Okuda T, Tasaki T, Nakata S, Yamashita K, Yoshioka H, Izumoto S, Kato A, Fujita M (2017) Efficacy of combination therapy with MET and VEGF inhibitors for MET-overexpressing glioblastoma. Anticancer Res 37(7):3871\u20133876","journal-title":"Anticancer Res"},{"key":"11127_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-5219-3","volume":"19","author":"EB Jo","year":"2019","unstructured":"Jo EB, Lee YS, Lee H, Park JB, Park H, Choi YL, Hong D, Kim SJ (2019) Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. BMC Cancer 19:1\u20132","journal-title":"BMC Cancer"},{"issue":"1","key":"11127_CR115","volume":"13","author":"S Huang","year":"2024","unstructured":"Huang S, Long Y, Gao Y, Lin W, Wang L, Jiang J, Yuan X, Chen Y, Zhang P, Chu Q (2024) Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation. Exp Hematol Oncol 13(1):97","journal-title":"Exp Hematol Oncol"},{"key":"11127_CR116","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","volume":"42","author":"A Puccini","year":"2019","unstructured":"Puccini A, Mar\u00edn-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, Loupakis F, Battaglin F (2019) Safety and tolerability of c-MET inhibitors in cancer. Drug Saf 42:211\u2013233","journal-title":"Drug Saf"},{"issue":"11","key":"11127_CR117","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","volume":"18","author":"DV Catenacci","year":"2017","unstructured":"Catenacci DV, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA (2017) Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(11):1467\u20131482","journal-title":"Lancet Oncol"},{"issue":"8","key":"11127_CR118","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.4251\/wjgo.v16.i8.3397","volume":"16","author":"WJ Wei","year":"2024","unstructured":"Wei WJ, Hong YL, Deng Y, Wang GL, Qiu JT, Pan F (2024) Research progress on the development of hepatocyte growth factor\/c-Met signaling pathway in gastric cancer: a review. World J Gastrointest Oncol 16(8):3397","journal-title":"World J Gastrointest Oncol"},{"key":"11127_CR119","volume":"11","author":"H Liao","year":"2021","unstructured":"Liao H, Tian T, Sheng Y, Peng Z, Li Z, Wang J, Li Y, Zhang C, Gao J (2021) The significance of MET expression and strategies of targeting MET treatment in advanced gastric cancer. Front Oncol 11:719217","journal-title":"Front Oncol"},{"issue":"32","key":"11127_CR120","doi-asserted-by":"crossref","first-page":"E2987","DOI":"10.1073\/pnas.1302725110","volume":"110","author":"M Merchant","year":"2013","unstructured":"Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L (2013) Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 110(32):E2987-96","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"11127_CR121","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cllc.2016.09.013","volume":"18","author":"H Wakelee","year":"2017","unstructured":"Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, Mekhail T, Lowe T, Sch\u00fctte W, Lena H, Lawler W, Braiteh F, Cosgriff T (2017) Efficacy and safety of onartuzumab in combination with first-line bevacizumab-or pemetrexed-based chemotherapy regimens in advanced non-squamous non\u2013small-cell lung cancer. Clin Lung Cancer 18(1):50\u201359","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"11127_CR122","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09460-2","volume":"7","author":"DM DiCara","year":"2017","unstructured":"DiCara DM, Chirgadze DY, Pope AR, Karatt-Vellatt A, Winter A, Slavny P, Van Den Heuvel J, Parthiban K, Holland J, Packman LC, Mavria G (2017) Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain. Sci Rep 7(1):9000","journal-title":"Sci Rep"},{"issue":"9","key":"11127_CR123","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/annonc\/mdv263","volume":"26","author":"V Di\u00e9ras","year":"2015","unstructured":"Di\u00e9ras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR, Xiao Y, Shames DS, Mocci S (2015) Randomized, phase II, placebo-controlled trial of onartuzumab and\/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol 26(9):1904\u20131910","journal-title":"Ann Oncol"},{"issue":"4","key":"11127_CR124","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1254\/jphs.11181FP","volume":"118","author":"Y Liu","year":"2012","unstructured":"Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro SI, Onodera S, Ikejima T (2012) Activation of ERK\u2013p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. J Pharmacol Sci 118(4):423\u2013432","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"11127_CR125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12029-024-01122-7","volume":"56","author":"J Jia","year":"2025","unstructured":"Jia J, Moyer A, Lowe M, Bolch E, Kortmansky J, Cho M, Lenz HJ, Kalyan A, Niedzwiecki D, Strickler JH (2025) A phase 2 study of Savolitinib in patients with MET amplified metastatic colorectal cancer. J Gastrointest Cancer 56(1):1\u20137","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"11127_CR126","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ijc.30049","volume":"139","author":"C Eng","year":"2016","unstructured":"Eng C, Bessudo A, Hart LL, Severtsev A, Gladkov O, M\u00fcller L, Kopp MV, Vladimirov V, Langdon R, Kotiv B, Barni S (2016) A randomized, placebo-controlled, phase 1\/2 study of Tivantinib (ARQ 197) in combination with Irinotecan and cetuximab in patients with metastatic colorectal cancer with wild\u2010type KRAS who have received first\u2010line systemic therapy. Int J Cancer 139(1):177\u2013186","journal-title":"Int J Cancer"},{"key":"11127_CR127","unstructured":"ClinicalTrials.gov Lung-MAP trial: Capmatinib, Osimertinib, and Ramucirumab for NSCLC (NCT05642572). U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05642572"},{"key":"11127_CR128","unstructured":"Combining targeted drugs for advanced non-small cell lung cancer with EGFR mutations and MET amplification. Available from: https:\/\/www.swog.org\/patients\/trials-open-patients\/combining-targeted-drugs-advanced-non-small-cell-lung-cancer-has-egfr"},{"key":"11127_CR129","unstructured":"UAMS Cancer Institute NCT06031688: Expanded Lung-MAP Trial Investigating Tepotinib with or Without Ramucirumab in Advanced NSCLC. Available from: https:\/\/cancer.uams.edu\/kb\/nct06031688\/"},{"key":"11127_CR130","unstructured":"Memorial Sloan Kettering Cancer Center Clinical Trial 24\u2009\u2013\u2009016: Investigating Targeted Therapies in Cancer Treatment. Available from: https:\/\/www.mskcc.org\/cancer-care\/clinical-trials\/24-016"},{"issue":"12","key":"11127_CR131","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","volume":"17","author":"A Drilon","year":"2016","unstructured":"Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG (2016) Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol 17(12):1653\u20131660 Epub 2016 Nov 4. PMID: 27825636; PMCID: PMC5143197","journal-title":"Lancet Oncol"},{"key":"11127_CR132","unstructured":"MyCancerGenome, NCT01639508 : Clinical trial investigating targeted therapies in cancer. Available from: https:\/\/www.mycancergenome.org\/content\/clinical_trials\/NCT01639508\/"},{"key":"11127_CR133","unstructured":"ClinicalTrials.gov NCT03175224: APL-101 in MET-Altered Tumors. U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03175224"},{"key":"11127_CR134","unstructured":"National Cancer Institute NCI-2023-04100: Amivantamab in Combination with Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCI-2023-04100"},{"key":"11127_CR135","unstructured":"National Cancer Institute NCI-2023-08689: Clinical trial investigating C-MET inhibitors in cancer treatment. Available from: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2023-08689loc=0q=c-met%20inhibitorsrl=1"},{"issue":"Suppl 4","key":"11127_CR136","first-page":"S813","volume":"31","author":"BC Cho","year":"2020","unstructured":"Cho BC et al (2020) 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann Oncol 31(Suppl 4):S813","journal-title":"Ann Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11127-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11127-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11127-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:31:58Z","timestamp":1767241918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11127-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11127"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11127-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This review article is based exclusively on previously published literature and does not involve any studies with human participants or animals conducted by the authors. Hence, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"1041"}}